Creatine kinase-myocardial band isoenzyme elevation after percutaneous coronary interventions using sirolimus-eluting stents.
We evaluated predictors of increased periprocedural creatine kinase-MB isoenzyme levels after implantation of sirolimus-eluting stents with an intent to fully cover the diseased segment. The total stent length per patient (predisposing factor) and elective use of glycoprotein IIb/IIIa (protective factor) were independent predictors of increased creatine kinase-MB isoenzyme levels.
Stankovic
Goran
G
EMO Centro Cuore Columbus, 48 Via Buonarroti, 20145 Milan, Italy. info@emocolumbus.it
Chieffo
Alaide
A
Iakovou
Ioannis
I
Orlic
Dejan
D
Corvaja
Nicola
N
Sangiorgi
Giuseppe
G
Airoldi
Flavio
F
Colombo
Antonio
A
D015906:Angioplasty, Balloon, Coronary; D023903:Coronary Restenosis / Q000517:prevention & control; D023921:Coronary Stenosis / Q000378:metabolism / Q000628:therapy*; D003402:Creatine Kinase / Q000378:metabolism*; D052279:Creatine Kinase, MB Form; D016208:Databases, Factual / Q000706:statistics & numerical data; D004867:Equipment Design; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D007527:Isoenzymes / Q000378:metabolism*; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000378:metabolism / Q000628:therapy; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D020123:Sirolimus / Q000008:administration & dosage*; D015607:Stents; D013997:Time Factors
D007166:Immunosuppressive Agents; D007527:Isoenzymes; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D003402:Creatine Kinase; D052279:Creatine Kinase, MB Form; D020123:Sirolimus